Overview

Concert Pharmaceuticals is a clinical stage biotechnology company pioneering the use of deuterium in medicinal chemistry. Concert applies its proprietary DCE Platform (deuterated chemical entity) to approved drugs and other agents with known human pharmacological activity to create novel medicines with the potential for enhanced efficacy, better tolerability and improved safety. By leveraging the large body of knowledge on known drugs, Concert focuses its efforts on valuable opportunities where deuterium modification may provide important medical benefits.

Media Contact:
Justine Koenigsberg
Senior Director, Corporate Communications and Investor Relations
781.674.5284
IR@concertpharma.com

Concert Materials and Related Stories

• Corporate Fact Sheet
• Management Backgrounder

Concert Publications

• May 2010, Drug Discovery & Development, "Chemistry for Drug Development: Deuterium Modification"
• March 2010, Innovations in Pharmaceutical Technology, "The Development of Deuterium-Containing Drugs"

The following is a selection of news stories in which Concert is featured:

• July 2010, Xconomy, "Concert Pharmaceuticals offers inside glimpse"
• May 2010, The Scientist, "Billion-Dollar Babies; The story of scientists who came up with ideas that recently convinced Pharma to give them millions of dollars"
• January 2010, In Vivo Start Up, "Start-Ups Across Health Care - Concert Pharmaceuticals"
• January 2010, Life Science Leader, "Women In Biopharma: Analyzing The Glass Ceiling"
• November 4, 2009, Mass High Tech, "MHT All-Star Roger Tung: Life Saver"
• October 19, 2009, Chemical & Engineering News, "Rising to the Challenge; In biotech, a culture of creativity and team building helps top companies to work for weather a tough economy"
• July 2009, Drug Discovery News, "Deuterium Discovery Deal"
• June 2009, Chemical & Engineering News, "Heavy-Hydrogen Drugs Turn Heads, Again"
• June 2009, Chemistry World, "Concert Arranges Billion Dollar GSK Deal"
  

Archive of news stories

• Watch Concert Interview on BioBusiness TV (February 2009)
  Streaming Video ¦ High Resolution Video
  

Awards and Recognition

 

	Ernst & Young Entrepreneur of the Year New England Finalist: Roger Tung
	Mass High Tech: Roger Tung Awarded 2009 All-Star Award
	OnDc: Named one of the OnDC's 100 Top Private Companies of 2009
	5th Annual Scrip Awards: 2009 Shortlist in the category of Licensing Deal of the Year
	Boston Business Journal: One of the area's largest venture-funded startups, December 2008
	2008 Fierce 15 Biotechnology Company, June 2008

 

[ back to top ]